Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)
September 29 2017 - 5:10PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 28, 2017
Galena Biopharma, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-33958
|
|
20-8099512
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
2000 Crow Canyon Place, Suite 380
San Ramon, CA 94583
|
|
94583
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code: (855) 855-4253
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the
following provisions:
☒
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this
chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth
company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
On September 28, 2017, Galena Biopharma, Inc. issued a press release entitled
Galena Biopharma Announces Completion of Enrollment in Two NeuVax (nelipepimut-S) Clinical Trials in Combination with Trastuzumab
. A copy of the press release is filed as Exhibit 99.1 to this Current
Report on Form 8-K and is incorporated by reference herein.
Item 9.01.
|
Financial Statements and Exhibits.
|
Exhibit Index
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its
behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
Galena Biopharma, Inc.
|
Dated: September 29, 2017
|
|
|
|
By:
|
|
/s/ Stephen F. Ghiglieri
|
|
|
|
|
|
|
Stephen F. Ghiglieri
|
|
|
|
|
|
|
Interim Chief Executive Officer & Chief Financial Officer
|
SELLAS Life Sciences (NASDAQ:SLS)
Historical Stock Chart
From Mar 2024 to Apr 2024
SELLAS Life Sciences (NASDAQ:SLS)
Historical Stock Chart
From Apr 2023 to Apr 2024